Cash-pay compounded and insurance-routed branded are two fundamentally different paths to GLP-1 therapy. The right choice depends almost entirely on your insurance situation. Cash-pay is predictable but limited to compounded (not FDA-approved finished drugs). Insurance routes you to branded but the math varies dramatically.
Side-by-side
| Dimension | Cash-pay compounded | Insurance + branded |
|---|---|---|
| Editorial score | 0/100 | 0/100 |
| Semaglutide | $145–$215/mo | $25–$1,349/mo |
| Tirzepatide | — | — |
Who should pick Cash-pay compounded
Patients without insurance for GLP-1 medications; patients with insurance that excludes weight management; patients who want predictable low monthly cost.
Who should pick Insurance + branded
Patients with insurance covering Wegovy or Zepbound at meaningful copay; patients who want indication-specific approved labeling.
Frequently asked
How to decide?
Call your insurer's member services. Ask: (1) is the medication on formulary, (2) what tier, (3) PA criteria, (4) expected copay. If $25–$100/mo copay with reasonable PA, insurance route. If denied or $200+ copay, cash-pay compounded is typically lower total.
Can I switch?
Yes. Many patients start cash-pay compounded for fast access then switch to insurance-routed once PA is approved.
Out-of-pocket caps?
Most commercial plans have annual out-of-pocket maximums. If you're approaching it for other reasons, branded with high copay may net out cheaper.